Drug development faces significant challenges, including increased complexity, rising costs, and ethical considerations. AI is transforming preclinical and clinical research by optimizing study design, automating data analysis, and improving decision-making. In vitro experiments benefit from AI-driven predictive analytics and imaging analyses, while clinical trials benefit from enhanced recruiting and scheduling strategies. AI has revolutionized drug discovery, but in vivo study design remains a critical challenge. This white paper explores how AI is changing the biomedical research landscape from basic research to clinical trials, emphasizing how AI-driven platforms like ModernVivo leverage technological advances to streamline and enhance in vivo study design.
Challenges in Drug Development and the AI Revolution
Drug development is a complex and demanding process. Bringing a drug through development and clinical trials has always been costly and difficult1. However, in today's world, researchers face increasing obstacles that not only jeopardize the success of drug discovery projects but also pile significant pressure on researchers and team leaders2.
Challenges Facing Drug Discovery Teams
Preclinical drug development is becoming increasingly complex due to advanced biomolecule and cell-based therapies, big data integration, and sophisticated testing methods, all of which drive up costs and regulatory demands3. Additionally, ethical considerations around animal welfare and human-derived samples add further challenges for drug discovery teams.
- Increased Complexity - The use of complex biomolecules and cells as therapeutic agents introduces additional ethical considerations in clinical applications4. These advancements also necessitate the development of more sophisticated testing assays to evaluate intricate mechanisms of action and potential toxicities5. Additionally, the rise of "big data" and large-scale omics datasets adds complexity to analysis and data-driven decision-making, especially when researchers lack the proper tools to manage and interpret datasets effectively6,7.
- Rising Costs - The cost of bringing a new drug to market has risen significantly in recent years1,8. The increasing complexity of therapeutics requires more costly and advanced production infrastructure. Developing sophisticated preclinical models, such as iPSC-based models or organoids, also adds to the expense of modern drug development9,10. Furthermore, strict regulatory requirements for toxicology testing further increase costs by requiring increased testing.
- Ethical Considerations - The impact of preclinical research on animal welfare has come into greater focus in recent years, meaning researchers must make greater considerations when designing experiments and entire preclinical workflows11,12. Human-derived therapies and models introduce additional ethical complexities and researchers must continuously adapt to evolving compliance standards13.
AI as a Solution to Modern Drug Discovery Challenges
AI is driving significant advancements across the biomedical landscape, from streamlining basic research processes to assisting clinicians with diagnostics and patient care14,15. Its impact is also evident in the preclinical stage, where it is revolutionizing study design to create more efficient and informative experiments. Modern AI tools like ModernVivo are already helping to drive advancements in areas like alcohol addiction and pancreatic cancer research. Machine learning models enable researchers to efficiently evaluate drug candidates without physical testing, including toxicology studies16. By enhancing efficiency, reproducibility, and decision-making, AI ultimately accelerates drug discovery and facilitates the development of new therapies to address critical clinical challenges.
AI-Powered Advances in In Vitro Experimental Design
AI is redefining in vitro research by boosting efficiency, accuracy, and ethical alignment.
Screening
Researchers can use AI-driven predictive analytics to improve in vitro studies by forecasting experimental results, optimizing assay conditions, and identifying or refining potential drug candidates17. Machine learning models can analyze vast and diverse datasets, including genomics, proteomics, and previous assay outcomes, to detect patterns, minimizing trial-and-error cycles and reducing costs18. By integrating multi-omics data, AI improves decision-making, accelerates drug discovery, and enhances the reproducibility of preclinical research. Integrating modern AI with computational methods is expected to shorten the drug candidate screening process from as long as six years to just one year or less16.
Image Analysis Deep Learning
Deep learning facilitates the rapid and automated analysis of intricate cellular structures and interactions in imaging data. It helps the study of cellular mechanisms and enhances pathology research by rapidly analysing stained tissue sections7,19. Unlike human operators, AI can identify subtle phenotypic changes, increasing the sensitivity of drug screening20. This technology can accelerate biomarker discovery and aid early disease modeling, significantly improving the efficiency of preclinical research21. For instance, researchers have recently leveraged AI to analyze chromatin imaging from PBMCs in patient blood to generate potential prognosis biomarkers22.
Data Processing and Interpretation
AI automates the integration and analysis of vast datasets produced from modern preclinical in vitro experiments, meaning researchers can quickly extract meaningful insights23. Machine learning algorithms integrate multi-source data, revealing hidden correlations that can drive hypothesis generation and help with protocol optimization24. For example, AI is being explored for its potential to integrate endoscopy and histology data to improve disease scoring and prognosis in inflammatory bowel disease patients25.
Innovators Driving AI-Powered In Vitro Research
Many companies are tailoring AI to solve longstanding challenges and bottlenecks in in vitro studies.
- Insilico Medicine: Uses AI to analyze multi-omics data, identify drug candidates, and streamline high-throughput screening, reducing trial and error in early-stage research.
- Schrödinger: Employs AI and physics-based simulations to enhance in vitro studies, allowing researchers to model biochemical interactions and refine experimental parameters virtually.
- Deep Genomics: Integrates AI with in vitro experimental design to analyze genomic data, accelerating RNA therapy research.
Transforming Clinical Trial Study Design with AI
Clinical trials have greatly benefited from various AI-powered processes that assist in design, participant recruitment, and data analysis.
Digital Biomarkers
Digital biomarkers are an emerging field without a widely accepted consensus on their definition. However, they are generally understood as data points collected from digital sources, such as health-tracking devices and apps. Examples include pedometers, blood oxygen monitors, skin temperature sensors, sleep trackers, eye-tracking technology, and heart rate monitors. Like traditional biomarkers, these data points can help assess patient risk and identify ideal cohorts for clinical trials26.
Digital Twin
Digital twins in clinical trials are virtual models of individual patients created using real-time data, AI, and predictive analytics. These digital replicas allow researchers to simulate treatment responses, optimize trial designs, and personalize interventions. By reducing reliance on physical participants, digital twins enhance trial efficiency, lower costs, and minimize patient risk. For instance, digital twins could lead to a 33% reduction in control arm sizes for clinical trials, significantly reducing costs and potentially speeding up trial progress27. They also enable continuous monitoring and allow researchers to adopt better recruitment practices. As technology advances, digital twins are expected to revolutionize clinical research, leading to faster, more accurate medical breakthroughs15,28.
Optimized Clinical Trials
AI enhances the efficiency of recruitment processes by allowing researchers to quickly analyze and interpret large, diverse patient datasets, ensuring the selection of the most appropriate patient cohorts29. This enhances patient stratification, a crucial factor in increasing clinical trial success rates and maintaining patient safety throughout the study. By optimizing participant selection, AI may reduce variability and improve trial outcomes30. AI may also be able to improve patient retention in trials. One study found that 80% of healthcare professionals preferred the answer to patients' questions generated by ChatGPT than by a doctor31.
AI also plays a vital role in defining trial endpoints and designing studies with clear and meaningful objectives. This includes indication discovery, where AI analyzes extensive datasets to identify potential new applications for existing, approved therapies, thereby expanding treatment options and accelerating drug repurposing efforts32–34.
Innovators in AI-driven Clinical Trials
- AiCure: Uses AI-powered computer vision and analytics to monitor patient adherence and engagement in clinical trials, improving data reliability.
- Owkin: Applies AI and federated learning to optimize patient selection, predict treatment responses, and enhance trial design.
The Gap in In Vivo Study Design AI Tools
AI has significantly improved nearly every aspect of biomedical research, including planning, execution, and analysis. These advancements extend to clinical trials, where AI is driving efficiency and innovation15. However, AI-driven tools for designing in vivo study protocols have lagged behind. This gap is particularly problematic for researchers, as in vivo studies remain a critical component of preclinical research and are under constant pressure for refinement and improvement12,35.
In vivo research urgently needs modernization due to persistent challenges that make studies difficult to conduct and limit the usefulness of their results in advancing new therapies. One major issue is data variability, an inherent challenge in biological research that becomes even greater when working with complex biological systems36,37. Currently, there are no standardized AI tools for designing in vivo studies, making it difficult to develop optimal protocols, especially ones that align with evolving regulatory standards. Researchers often have to sift through vast literature databases or rely on outdated legacy protocols that fail to meet modern research or ethical standards.
Challenges and Implications of Variability in Biomedical Research
The formalin pain test is a widely used model for evaluating inflammatory pain and has been in use since the 1970s38. An unfiltered PubMed search yields over 6000 results for the keywords “formalin pain.” Since so many studies have used this model, researchers have made countless different experimental design choices (e.g., different doses, routes of administration, behavioral scoring methods). Thus, there is no centralized way to analyze or standardize these variations, making it incredibly difficult for researchers to decide on a protocol for their work. Furthermore, sifting through 6000 papers simply isn’t a realistic option.
These variability issues extend to fields like Alzheimer’s disease research in which different genetic mutations, amyloid-beta injection protocols, and behavioral tests, make it hard to compare results across studies39. Many longstanding biomedical fields face similar challenges to varying degrees, making it difficult for researchers to standardize methodologies and draw reliable conclusions.
As it has in many other fields, AI has the potential to revolutionize in vivo study design, equipping researchers with the tools they need to overcome longstanding challenges and drive the next wave of therapeutic advancements.
The ModernVivo Solution
ModernVivo is an AI-powered platform designed to instantly and comprehensively analyze literature databases, enabling researchers to efficiently develop and refine in vivo research protocols. It supports every aspect of in vivo studies, ensuring that all critical details—such as dosage, housing conditions, models, and optimal endpoints—are thoroughly covered.
The Future of AI in Drug Discovery Design
AI's role in study design is only beginning to be fully understood as new technologies emerge and gain mainstream adoption. While a certain level of caution is natural and beneficial, researchers must identify the optimal time to adopt AI-driven solutions to stay competitive. The question is no longer if but when.
AI is becoming increasingly skilled at generating hypotheses by integrating vast datasets from diverse sources, such as compound structures, binding sites, scientific literature, clinical data, and trial results. Looking ahead, it is valuable to identify where AI can enhance existing workflows rather than invent new ones. This efficiency-driven approach has already enabled AI to link compounds to specific disease contexts, uncover research gaps, and identify new uses for existing drugs—bypassing the extensive research, testing, and regulatory challenges associated with manual methods. By identifying the areas where AI is currently lacking, researchers and team leaders can anticipate and strategically prepare for the next breakthrough. Perhaps the most significant opportunity for transformation lies in in vivo study design.
In Vivo Study Design
AI is the clear and long-overdue solution for optimizing in vivo study design, a process that simply cannot be modernized while using manual methods. Researchers often rely on familiar or legacy approaches to in vivo experiments, making only small adjustments to improve outcomes incrementally. However, with vast amounts of existing literature and data from previous experiments, sticking to conventional methods means missing both critical details and broader design elements, such as model selection. AI can integrate this wealth of information, providing researchers with the best opportunities for success in in vivo studies. This, in turn, reduces the time and resources required, streamlining study processes and generating higher-quality data. Beyond improving workflows, AI-driven in vivo study design can enhance translational research quality and help address key challenges related to reproducibility and clinical trial success.
Take the Next Step: Embrace AI in Your In Vivo Study Design with ModernVivo
Life science researchers face increasing pressure to optimize in vivo study design while ensuring accuracy, efficiency, and reproducibility. AI-powered solutions like ModernVivo revolutionize this process by leveraging advanced algorithms to streamline study planning and minimize variability. With AI-driven insights, researchers can refine dosing strategies, predict outcomes more effectively, and reduce unnecessary animal use12.
ModernVivo provides a cutting-edge platform that replaces month-long literature searches with rapid yet robust database interrogation. Adopting AI in your research planning gives you a competitive edge and improves study outcomes.
Stay ahead of the curve in drug discovery innovation. Sign up for our newsletter to receive the latest insights on AI-driven advancements in in vivo study design and unlock the full potential of ModernVivo for your research.
References
1. Speed up biopharma clinical trials to boost R&D output | McKinsey. Accessed March 7, 2025. https://www.mckinsey.com/industries/life-sciences/our-insights/accelerating-clinical-trials-to-improve-biopharma-r-and-d-productivity
2. Peralta G, Sánchez-Santiago B. Navigating the challenges of clinical trial professionals in the healthcare sector. Front Med. 2024;11:1400585. doi:10.3389/fmed.2024.1400585
3. Markey N, Howitt B, El-Mansouri I, Schwartzenberg C, Kotova O, Meier C. Clinical trials are becoming more complex: a machine learning analysis of data from over 16,000 trials. Sci Rep. 2024;14(1):3514. doi:10.1038/s41598-024-53211-z
4. Bashor CJ, Hilton IB, Bandukwala H, Smith DM, Veiseh O. Engineering the next generation of cell-based therapeutics. Nat Rev Drug Discov. 2022;21(9):655-675. doi:10.1038/s41573-022-00476-6
5. Pognan F, Beilmann M, Boonen HCM, et al. The evolving role of investigative toxicology in the pharmaceutical industry. Nat Rev Drug Discov. 2023;22(4):317-335. doi:10.1038/s41573-022-00633-x
6. Jiang P, Sinha S, Aldape K, Hannenhalli S, Sahinalp C, Ruppin E. Big data in basic and translational cancer research. Nat Rev Cancer. 2022;22(11):625-639. doi:10.1038/s41568-022-00502-0
7. Dinsdale NK, Bluemke E, Sundaresan V, Jenkinson M, Smith SM, Namburete AIL. Challenges for machine learning in clinical translation of big data imaging studies. Neuron. 2022;110(23):3866-3881. doi:10.1016/j.neuron.2022.09.012
8. Sertkaya A, Beleche T, Jessup A, Sommers BD. Costs of Drug Development and Research and Development Intensity in the US, 2000-2018. JAMA Netw Open. 2024;7(6):e2415445. doi:10.1001/jamanetworkopen.2024.15445
9. Cerneckis J, Cai H, Shi Y. Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications. Sig Transduct Target Ther. 2024;9(1):112. doi:10.1038/s41392-024-01809-0
10. Thorel L, Perréard M, Florent R, et al. Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology. Exp Mol Med. 2024;56(7):1531-1551. doi:10.1038/s12276-024-01272-5
11. FDA no longer needs to require animal tests before human drug trials. Accessed March 7, 2025. https://www.science.org/content/article/fda-no-longer-needs-require-animal-tests-human-drug-trials
12. The 3Rs | NC3Rs. Accessed October 21, 2024. https://nc3rs.org.uk/who-we-are/3rs
13. Loewa A, Feng JJ, Hedtrich S. Human disease models in drug development. Nat Rev Bioeng. 2023;1(8):545-559. doi:10.1038/s44222-023-00063-3
14. Alowais SA, Alghamdi SS, Alsuhebany N, et al. Revolutionizing healthcare: the role of artificial intelligence in clinical practice. BMC Med Educ. 2023;23(1):689. doi:10.1186/s12909-023-04698-z
15. Zhang K, Yang X, Wang Y, et al. Artificial intelligence in drug development. Nat Med. 2025;31(1):45-59. doi:10.1038/s41591-024-03434-4
16. Sadybekov AV, Katritch V. Computational approaches streamlining drug discovery. Nature. 2023;616(7958):673-685. doi:10.1038/s41586-023-05905-z
17. Chen Z, Min MR, Parthasarathy S, Ning X. A deep generative model for molecule optimization via one fragment modification. Nat Mach Intell. 2021;3(12):1040-1049. doi:10.1038/s42256-021-00410-2
18. Bhhatarai B, Walters WP, Hop CECA, Lanza G, Ekins S. Opportunities and challenges using artificial intelligence in ADME/Tox. Nat Mater. 2019;18(5):418-422. doi:10.1038/s41563-019-0332-5
19. Wang S, Rong R, Zhou Q, et al. Deep learning of cell spatial organizations identifies clinically relevant insights in tissue images. Nat Commun. 2023;14(1):7872. doi:10.1038/s41467-023-43172-8
20. Vincent F, Nueda A, Lee J, Schenone M, Prunotto M, Mercola M. Phenotypic drug discovery: recent successes, lessons learned and new directions. Nat Rev Drug Discov. 2022;21(12):899-914. doi:10.1038/s41573-022-00472-w
21. Prelaj A, Miskovic V, Zanitti M, et al. Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review. Ann Oncol. 2024;35(1):29-65. doi:10.1016/j.annonc.2023.10.125
22. Challa K, Paysan D, Leiser D, Sauder N, Weber DC, Shivashankar GV. Imaging and AI based chromatin biomarkers for diagnosis and therapy evaluation from liquid biopsies. npj Precis Onc. 2023;7(1):135. doi:10.1038/s41698-023-00484-8
23. Li H, Han Z, Sun Y, et al. CGMega: explainable graph neural network framework with attention mechanisms for cancer gene module dissection. Nat Commun. 2024;15(1):5997. doi:10.1038/s41467-024-50426-6
24. Alber M, Buganza Tepole A, Cannon WR, et al. Integrating machine learning and multiscale modeling—perspectives, challenges, and opportunities in the biological, biomedical, and behavioral sciences. npj Digit Med. 2019;2(1):115. doi:10.1038/s41746-019-0193-y
25. Iacucci M, Santacroce G, Zammarchi I, et al. Artificial intelligence and endo-histo-omics: new dimensions of precision endoscopy and histology in inflammatory bowel disease. The Lancet Gastroenterology & Hepatology. 2024;9(8):758-772. doi:10.1016/S2468-1253(24)00053-0
26. Macias Alonso AK, Hirt J, Woelfle T, Janiaud P, Hemkens LG. Definitions of digital biomarkers: a systematic mapping of the biomedical literature. BMJ Health Care Inform. 2024;31(1):e100914. doi:10.1136/bmjhci-2023-100914
27. Buntz B. Digital twins in Alzheimer’s trials enable smaller sample sizes. Drug Discovery and Development. August 23, 2024. Accessed March 20, 2025. https://www.drugdiscoverytrends.com/how-digital-twins-could-support-more-affordable-alzheimers-research/
28. Chandra S, Prakash PKS, Samanta S, Chilukuri S. ClinicalGAN: powering patient monitoring in clinical trials with patient digital twins. Sci Rep. 2024;14(1):12236. doi:10.1038/s41598-024-62567-1
29. Lu X, Chen M, Lu Z, Shi X, Liang L. Artificial intelligence tools for optimising recruitment and retention in clinical trials: a scoping review protocol. BMJ Open. 2024;14(3):e080032. doi:10.1136/bmjopen-2023-080032
30. Wang Y, Carter BZ, Li Z, Huang X. Application of machine learning methods in clinical trials for precision medicine. JAMIA Open. 2022;5(1):ooab107. doi:10.1093/jamiaopen/ooab107
31. Ayers JW, Poliak A, Dredze M, et al. Comparing Physician and Artificial Intelligence Chatbot Responses to Patient Questions Posted to a Public Social Media Forum. JAMA Intern Med. 2023;183(6):589. doi:10.1001/jamainternmed.2023.1838
32. Using Artificial Intelligence and Machine Learning in the Development of Drug and Biological Products; Availability. Federal Register. May 11, 2023. Accessed March 7, 2025. https://www.federalregister.gov/documents/2023/05/11/2023-09985/using-artificial-intelligence-and-machine-learning-in-the-development-of-drug-and-biological
33. Chopra H, Annu null, Shin DK, et al. Revolutionizing clinical trials: the role of AI in accelerating medical breakthroughs. Int J Surg. 2023;109(12):4211-4220. doi:10.1097/JS9.0000000000000705
34. Fu C, Chen Q. The future of pharmaceuticals: Artificial intelligence in drug discovery and development. Journal of Pharmaceutical Analysis. Published online February 2025:101248. doi:10.1016/j.jpha.2025.101248
35. Chang MCJ, Grieder FB. The continued importance of animals in biomedical research. Lab Anim. 2024;53(11):295-297. doi:10.1038/s41684-024-01458-4
36. Design preclinical studies for reproducibility. Nat Biomed Eng. 2018;2(11):789-790. doi:10.1038/s41551-018-0322-y
37. Von Kortzfleisch VT, Karp NA, Palme R, Kaiser S, Sachser N, Richter SH. Improving reproducibility in animal research by splitting the study population into several ‘mini-experiments.’ Sci Rep. 2020;10(1):16579. doi:10.1038/s41598-020-73503-4
38. Sawynok J, Liu XJ. The Formalin Test: Characteristics and Usefulness of the Model. Reviews in Analgesia. 2003;7(2):145-163. doi:10.3727/000000003783992982
39. Puzzo D, Lee L, Palmeri A, Calabrese G, Arancio O. Behavioral assays with mouse models of Alzheimer’s disease: practical considerations and guidelines. Biochem Pharmacol. 2014;88(4):450-467. doi:10.1016/j.bcp.2014.01.011
AI Disclosure: Some of this content was generated with assistance from AI tools for copywriting.
.png)
.png)
.png)
.avif)
